Table 1.

Primary and secondary outcomes assessed

Primary outcomes

Incidence of CMV infection (on the basis of a positive blood CMV PCR or antigenemia pp65 or as defined in included trials)

Incidence of BKPyV infection (on the basis of blood PCR >104 copies or urine PCR >107 copies or as defined in included trials) or a transplanted kidney biopsy typical of PyVAN

Secondary outcomes

Composite of the incidence of acute cellular rejection, AMR, or development of DSAs

Graft loss

Incidence of serious adverse events

Incidence of other viral, bacterial, or fungal infections

Incidence of PyVAN as defined by kidney biopsy

Incidence of CMV disease (retinitis, pneumonitis, hepatitis, or colitis)

Incidence of proteinuria

Incidence of wound-healing complications

eGFR or creatinine clearance at study termination

CMV, cytomegalovirus; BKPyV, BK polyoma virus; PyVAN, polyoma virus–associated nephropathy; AMR, antibody-mediated rejection; DSA, donor-specific antibody.